R. Stahel

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

Jeanette Lundin, Anders Österborg, G. Brittinger et al. · Journal of Clinical Oncology · 1998 · 258 citations

Pharmacy, Oncology, Pharmacotherapy +16

Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines

Uwe Zangemeister‐Wittke, T. Schenker, G. H. Luedke et al. · British Journal of Cancer · 1998 · 181 citations · Full text

Medicine, Oncology, Pharmacology +9

A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.

Uwe Zangemeister‐Wittke, Siân H. Leech, Robert A. Olie et al. · PubMed · 2000 · 155 citations

Life Sciences, Molecular Biology, Oncology +17

Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer

C. Manegold, Bengt Bergman, A. Chemaissani et al. · Annals of Oncology · 1997 · 114 citations · Full text

Medicine, Oncology, Pharmacology +14

Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial

Cesare Gridelli, C. Manegold, P Mali et al. · European Journal of Cancer · 2004 · 44 citations

Medicine, Pharmacology, Pharmacotherapy +3